Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Ovarian Cancer
What adjuvant therapy do you recommend in a primary non-gestational ovarian choriocarcinoma with mixed dysgerminoma and Yolk Sac tumor elements?
s/p fertility preservation surgery with USO.
Related Questions
Would you hold a PARP inhibitor in the perioperative period for an ileostomy reversal in a patient who has completed primary debulking surgery followed by chemotherapy?
What factors do you consider when deciding between 3 versus 4 cycles of BEP for ovarian germ cell tumors?
Do you routinely use prophylactic anticoagulation when treating ovarian cancer patients with neoadjuvant chemotherapy?
What platform do you use for HRD testing of ovarian cancers and why?
How would you approach adjuvant therapy for a patient who was diagnosed with surgically staged and completely resected stage II high-grade serous ovarian cancer while she prepared for neoadjuvant chemoradiation for rectal cancer?
Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?
For a patient with adenosarcoma of the ovary with high grade sarcomatous overgrowth removed intact with appropriate oncologic surgery, is there any role for radiation?
How do you counsel patients with homologous recombination repair proficient tumors already on niraparib maintenance therapy, prior to the FDA restriction?
How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?
How should PARP inhibitors be incorporated into clinical practice in later line/maintenance of platinum-sensitive ovarian cancer for PARP inhibitor-naïve patients?